2022
Hormone therapies in meningioma-where are we?
Miyagishima D, Moliterno J, Claus E, Günel M. Hormone therapies in meningioma-where are we? Journal Of Neuro-Oncology 2022, 161: 297-308. PMID: 36418843, PMCID: PMC10371392, DOI: 10.1007/s11060-022-04187-1.Peer-Reviewed Original ResearchConceptsPositive receptor statusReceptor statusSomatostatin analoguesClinical trialsHormone-related risk factorsMajority of patientsNIH Clinical Trials DatabaseClinical trials databasesStratification of patientsHormone therapyTrials databasesFuture trialsHormonal agentsSpecific therapyRisk factorsSomatostatin receptorsInclusion criteriaMEDLINE-PubMedMeningioma growthMost meningiomasTherapeutic potentialMeningiomasPatientsTherapyTrialsTumors of the Diffuse Neuroendocrine and Gastroenteropancreatic System
Vosburgh E. Tumors of the Diffuse Neuroendocrine and Gastroenteropancreatic System. 2022, 1-10. DOI: 10.1002/9781119000822.hfcm083.pub2.Peer-Reviewed Original ResearchPeptide receptor radiotherapyMultiple endocrine neoplasiaDiffuse neuroendocrine systemClinical featuresHepatic metastasesNeuroendocrine tumorsGastroenteropancreatic systemNeuroendocrine systemInformed clinical careUnique clinical syndromeOngoing clinical trialsAbsence of symptomsCancer registry dataUnexplained incidenceReceptor radiotherapyClinical presentationRandomized trialsTherapeutic optionsClinical syndromeMultiple myelomaSomatostatin analoguesSpecific therapyRecent trialsSurvival resultsClinical trialsA genomic meta-analysis of clinical variables and their association with intrinsic molecular subsets in systemic sclerosis
Franks JM, Toledo DM, Martyanov V, Wang Y, Huang S, Wood TA, Spino C, Chung L, Denton C, Derrett-Smith E, Gordon JK, Spiera R, Domsic R, Hinchcliff M, Khanna D, Whitfield ML. A genomic meta-analysis of clinical variables and their association with intrinsic molecular subsets in systemic sclerosis. Rheumatology 2022, 62: 19-28. PMID: 35751592, PMCID: PMC9788818, DOI: 10.1093/rheumatology/keac344.Peer-Reviewed Original ResearchConceptsMolecular subsetsIntrinsic subsetInflammatory subsetBaseline demographicsSSc patientsWhite/Caucasian patientsBaseline clinical demographicsAverage disease durationRodnan skin scoreAfrican American/BlackASSET trialUnique gene expression signatureDisease durationGene expression signaturesClinical demographicsParticipant seraSkin scoreSystemic sclerosisValidation cohortClinical variablesCaucasian patientsSpecific therapyAmerican/BlackSkin biopsiesDisease pathogenesisA Description of COVID-19-Directed Therapy in Children Admitted to US Intensive Care Units 2020
Schuster JE, Halasa NB, Nakamura M, Levy ER, Fitzgerald JC, Young CC, Newhams MM, Bourgeois F, Staat MA, Hobbs CV, Dapul H, Feldstein LR, Jackson AM, Mack EH, Walker TC, Maddux AB, Spinella PC, Loftis LL, Kong M, Rowan CM, Bembea MM, McLaughlin GE, Hall MW, Babbitt CJ, Maamari M, Zinter MS, Cvijanovich NZ, Michelson KN, Gertz SJ, Carroll CL, Thomas NJ, Giuliano JS, Singh AR, Hymes SR, Schwarz AJ, McGuire JK, Nofziger RA, Flori HR, Clouser KN, Wellnitz K, Cullimore ML, Hume JR, Patel M, Randolph AG, Investigators O. A Description of COVID-19-Directed Therapy in Children Admitted to US Intensive Care Units 2020. Journal Of The Pediatric Infectious Diseases Society 2022, 11: piab123-. PMID: 35022779, PMCID: PMC8807297, DOI: 10.1093/jpids/piab123.Peer-Reviewed Original ResearchConceptsCOVID-19-directed therapiesAcute coronavirus disease 2019Life-threatening COVID-19COVID-19Acute COVID-19Underlying medical conditionsIntensive care unitHigh-acuity careCoronavirus disease 2019Half of childrenYears of ageCharacteristics of childrenRemdesivir useSystemic steroidsRespiratory supportClinical courseCare unitPediatric hospitalSpecific therapyPediatric dataIll childrenLaboratory valuesDisease 2019Medical conditionsUS hospitals
2020
Combined Pharmacotherapy and Cognitive Behavioral Therapy for Adults With Alcohol or Substance Use Disorders
Ray LA, Meredith LR, Kiluk BD, Walthers J, Carroll KM, Magill M. Combined Pharmacotherapy and Cognitive Behavioral Therapy for Adults With Alcohol or Substance Use Disorders. JAMA Network Open 2020, 3: e208279. PMID: 32558914, PMCID: PMC7305524, DOI: 10.1001/jamanetworkopen.2020.8279.Peer-Reviewed Original ResearchConceptsSubstance use disordersAdult alcohol use disordersCognitive behavioral therapyUsual careRandomized clinical trialsUse disordersBehavioral therapySpecific therapyClinical trialsAddition of CBTSuperiority of CBTTreatment of SUDsUsual clinical managementForms of pharmacotherapyFirst-line interventionEvidence-based therapiesClinical trial samplesEvidence-based modalitiesAlcohol use disorderEnglish-language articlesPublic health concernFull-text articlesEffect sizeCochrane RegisterRandom effects estimatesPancreatic Cancer; Biomolecular and Genetic Aspects
Yoo J, Farrell J. Pancreatic Cancer; Biomolecular and Genetic Aspects. 2020, 30-38. DOI: 10.1016/b978-0-12-801238-3.65864-6.Peer-Reviewed Original ResearchPancreatic cancerGenetic aspectsNext-generation sequencingTranscriptomic analysisGenomic investigationsKey driver mutationsRecent translational advancesOverall survival rateMutational landscapeDiscrete molecular subtypesGeneration sequencingSpecific therapyLethal malignancyMolecular subtypesDisease processDriver mutationsSurvival rateTranslational advancesCancerPrecision medicineBiomolecularSequencingMutationsPathwayPatients
2019
A Meta-Analysis of Cognitive-Behavioral Therapy for Alcohol or Other Drug Use Disorders: Treatment Efficacy by Contrast Condition
Magill M, Ray L, Kiluk B, Hoadley A, Bernstein M, Tonigan JS, Carroll K. A Meta-Analysis of Cognitive-Behavioral Therapy for Alcohol or Other Drug Use Disorders: Treatment Efficacy by Contrast Condition. Journal Of Consulting And Clinical Psychology 2019, 87: 1093-1105. PMID: 31599606, PMCID: PMC6856400, DOI: 10.1037/ccp0000447.Peer-Reviewed Original ResearchConceptsCognitive behavioral therapyDrug use disordersUse disordersEffect sizeConsumption frequencyTime pointsEvidence-based therapiesPooled effect sizeMinimal treatmentEstimates of efficacyTest of heterogeneityCBT effectsNonspecific therapySpecific therapySuperior efficacyStudy-level moderatorsModerate heterogeneityTreatment efficacySignificant effect sizeMultivariate analysisMeta-analysisTherapyPublication biasStudy aimNonspecific controlPersonalizing Treatment Selection for Breast Cancer
Pusztai L, Yeoh C. Personalizing Treatment Selection for Breast Cancer. 2019, 297-324. DOI: 10.1201/9780429066504-14.Peer-Reviewed Original ResearchBreast cancerTreatment selectionClinical outcomesRisk of recurrenceMultiple treatment optionsParticular clinical outcomesCurrent treatment modalitiesCancer-related deathMore effective treatmentsProbability of benefitBreast cancer researchUnited States FoodSurgical resectionProbability of responseTrastuzumab therapyCommon malignancyTreatment optionsClinicopathologic variablesPatient preferencesSpecific therapyTreatment modalitiesMulti-gene testsDisease outcomeMolecular differencesEffective treatment
2018
Inhibition of profibrotic microRNA-21 affects platelets and their releasate
Barwari T, Eminaga S, Mayr U, Lu R, Armstrong PC, Chan MV, Sahraei M, Fernández-Fuertes M, Moreau T, Barallobre-Barreiro J, Lynch M, Yin X, Schulte C, Baig F, Pechlaner R, Langley SR, Zampetaki A, Santer P, Weger M, Plasenzotti R, Schosserer M, Grillari J, Kiechl S, Willeit J, Shah AM, Ghevaert C, Warner TD, Fernández-Hernando C, Suárez Y, Mayr M. Inhibition of profibrotic microRNA-21 affects platelets and their releasate. JCI Insight 2018, 3: e123335. PMID: 30385722, PMCID: PMC6238735, DOI: 10.1172/jci.insight.123335.Peer-Reviewed Original ResearchConceptsMiR-21 inhibitionMiR-21TGF-β1TGF-β1 secretionMiR-21 levelsMiR-21 mimicsMiR-21 inhibitorMurine cardiac fibroblastsBruneck StudyLow plateletsAntifibrotic effectsProfibrotic factorsLeukocyte countSpecific therapyClinical trialsOrgan diseaseTGF-β1 releaseLittermate controlsBone marrowCardiac fibroblastsMegakaryocyte numberMouse heartsFibrosisPlasma samplesPlatelet release
2017
Have we pushed the needle for treatment of Type 1 diabetes?
Naushad N, Perdigoto AL, Rui J, Herold KC. Have we pushed the needle for treatment of Type 1 diabetes? Current Opinion In Immunology 2017, 49: 44-50. PMID: 28992525, PMCID: PMC5937133, DOI: 10.1016/j.coi.2017.09.004.Peer-Reviewed Original ResearchCell Replacement Strategies for Parkinson’s Disease
Chatterjee D, Wakeman D, Kordower J. Cell Replacement Strategies for Parkinson’s Disease. Molecular And Translational Medicine 2017, 73-83. DOI: 10.1007/978-3-319-57153-9_4.Peer-Reviewed Original ResearchCell replacement strategiesFetal graftsClinical trialsParkinson's diseaseAnimal modelsDouble-blind clinical assessmentOpen-label clinical trialCareful subject selectionDopamine cell replacementGraft-induced dyskinesiaPotential clinical efficacyProgressive neurodegenerative disorderCell transplantation therapyPrion-like transmissionStem cellsGraft microenvironmentMotor dysfunctionMotor symptomsNigrostriatal pathwayClinical efficacyReplacement therapyDopaminergic neuronsLewy bodiesSpecific therapyCell replacement therapyPsychiatric comorbidity in Wilson’s disease
Mura G, Zimbrean PC, Demelia L, Carta MG. Psychiatric comorbidity in Wilson’s disease. International Review Of Psychiatry 2017, 29: 445-462. PMID: 28681670, DOI: 10.1080/09540261.2017.1311845.Peer-Reviewed Original ResearchConceptsWilson's diseasePsychiatric disordersCase-control studyAutosomal recessive inherited disorderPubMed/MEDLINERare autosomal recessive inherited disorderBetter life expectancyRecessive inherited disorderPsychiatric comorbidityCase reportSpecific therapyAvailable treatmentsPsychiatric disturbancesHigh prevalenceMood disordersPsychiatric symptomsPsychiatric outcomesClinical monitoringTherapeutic issuesPsychosocial outcomesInherited disorderRelevant articlesDiseaseGoogle ScholarCareful evaluation
2016
HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology
Bartley AN, Washington MK, Ventura CB, Ismaila N, Colasacco C, Benson AB, Carrato A, Gulley ML, Jain D, Kakar S, Mackay HJ, Streutker C, Tang L, Troxell M, Ajani JA. HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology. Archives Of Pathology & Laboratory Medicine 2016, 140: 1345-1363. PMID: 27841667, DOI: 10.5858/arpa.2016-0331-cp.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaBiomarkers, TumorClinical Decision-MakingCombined Modality TherapyDecision TreesDiagnosis, DifferentialEsophageal NeoplasmsEvidence-Based MedicineHumansMedical OncologyMolecular Diagnostic TechniquesMolecular Targeted TherapyMutationNeoplasm GradingNeoplasm StagingPathology, ClinicalReceptor, ErbB-2Societies, MedicalStomach NeoplasmsSystematic Reviews as TopicUnited StatesConceptsAdvanced gastroesophageal adenocarcinomaGastroesophageal adenocarcinomaEvidence-based guidelinesAssessment of HER2Clinical OncologyAmerican SocietyClinical decisionClinical pathologyAmerican PathologistsAccuracy of HER2Initial therapyMorphologic selectionOptimal HER2Combination chemotherapyHER2 statusOnly biomarkerSpecific therapyHER2 testingTumor specimensPatientsHER2Systematic reviewClinical implicationsNeoplastic tissueTherapyHER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma
Bartley AN, Washington MK, Ventura CB, Ismaila N, Colasacco C, Benson AB, Carrato A, Gulley ML, Jain D, Kakar S, Mackay HJ, Streutker C, Tang L, Troxell M, Ajani JA. HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma. American Journal Of Clinical Pathology 2016, 146: 647-669. PMID: 28077399, PMCID: PMC6272805, DOI: 10.1093/ajcp/aqw206.Peer-Reviewed Original ResearchConceptsAdvanced gastroesophageal adenocarcinomaGastroesophageal adenocarcinomaEvidence-based guidelinesAssessment of HER2Clinical decisionAmerican SocietyAccuracy of HER2Initial therapyMorphologic selectionOptimal HER2Combination chemotherapyHER2 statusOnly biomarkerSpecific therapyHER2 testingClinical OncologyTumor specimensPatientsHER2Systematic reviewClinical implicationsNeoplastic tissueTherapyClinical pathologyAmerican PathologistsHER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology
Bartley AN, Washington MK, Colasacco C, Ventura CB, Ismaila N, Benson AB, Carrato A, Gulley ML, Jain D, Kakar S, Mackay HJ, Streutker C, Tang L, Troxell M, Ajani JA. HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology. Journal Of Clinical Oncology 2016, 35: 446-464. PMID: 28129524, DOI: 10.1200/jco.2016.69.4836.Peer-Reviewed Original ResearchConceptsAdvanced gastroesophageal adenocarcinomaGastroesophageal adenocarcinomaEvidence-based guidelinesAssessment of HER2Clinical OncologyAmerican SocietyClinical decisionClinical pathologyAmerican PathologistsAccuracy of HER2Initial therapyMorphologic selectionOptimal HER2Combination chemotherapyHER2 statusOnly biomarkerSpecific therapyHER2 testingTumor specimensPatientsHER2Systematic reviewClinical implicationsNeoplastic tissueTherapyAnesthesia for Patients with Traumatic Brain Injuries
Bhattacharya B, Maung AA. Anesthesia for Patients with Traumatic Brain Injuries. Anesthesiology Clinics 2016, 34: 747-759. PMID: 27816132, DOI: 10.1016/j.anclin.2016.06.009.Peer-Reviewed Original ResearchFuture research directions to improve fistula maturation and reduce access failure
Hu H, Patel S, Hanisch JJ, Santana JM, Hashimoto T, Bai H, Kudze T, Foster TR, Guo J, Yatsula B, Tsui J, Dardik A. Future research directions to improve fistula maturation and reduce access failure. Seminars In Vascular Surgery 2016, 29: 153-171. PMID: 28779782, PMCID: PMC5547899, DOI: 10.1053/j.semvascsurg.2016.08.005.Peer-Reviewed Original ResearchConceptsArteriovenous fistulaAVF maturationAVF failurePatient selectionNeointimal hyperplasiaAccess failureEnd-stage renal diseaseDrastic hemodynamic changesSetting of uremiaAppropriate patient selectionCareful patient selectionNovel interventional techniquesVascular cell activationAlternative surgical strategiesPatient-specific outcomesFistula useSystemic inflammationRenal diseaseFistula maturationInflammatory mediatorsHemodynamic changesSurgical strategyVascular accessSpecific therapyFistula anastomosisPersonalized Medicine Approaches in Prostate Cancer Employing Patient Derived 3D Organoids and Humanized Mice
Bartucci M, Ferrari A, Kim I, Ploss A, Yarmush M, Sabaawy H. Personalized Medicine Approaches in Prostate Cancer Employing Patient Derived 3D Organoids and Humanized Mice. Frontiers In Cell And Developmental Biology 2016, 4: 64. PMID: 27446916, PMCID: PMC4917534, DOI: 10.3389/fcell.2016.00064.Peer-Reviewed Original ResearchProstate cancerTumor initiating cellsHuman immune systemHumanized miceTherapeutic responsePersonalized therapeutic responseAdaptive T cellsPrimary prostate cancerPatient-derived organoidsPersonalized medicine approachPCa microenvironmentSelective engraftmentImmunotherapy approachesCommon malignancyCancer deathSpecific therapyImmune cellsDisease progressionCancer precision medicineCommon causeT cellsChimeric antigenPatient-specific therapiesMouse modelTherapy resistanceCost-effectiveness of Confirmatory Testing Before Treatment of Onychomycosis
Mikailov A, Cohen J, Joyce C, Mostaghimi A. Cost-effectiveness of Confirmatory Testing Before Treatment of Onychomycosis. JAMA Dermatology 2016, 152: 1-6. PMID: 26716567, DOI: 10.1001/jamadermatol.2015.4190.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAdministration, TopicalAlgorithmsCost SavingsCost-Benefit AnalysisDecision Support TechniquesDecision TreesHealth Care CostsHumansHydroxidesNaphthalenesOnychomycosisPeriodic Acid-Schiff ReactionPotassium CompoundsPotentially Inappropriate Medication ListTerbinafineTriazolesConceptsConfirmatory testingOral terbinafineSystemic therapyDirect patient evaluationLiver toxic effectsPatient cost savingsPotassium hydroxide (KOH) stainDisease prevalenceTreatment of onychomycosisConfirmatory diagnostic testingHealth care professionalsPrevalence of diseaseTerbinafine therapyEmpirical therapyPretreatment testingPrimary outcomePatient evaluationSpecific therapyEmpirical treatmentMAIN OUTCOMECare professionalsInternational guidelinesTherapyDiagnostic testingPatient safetyIntroduction and Survey Results
Garcia-Tsao G, Ripoll C, Augustin S, Reiberger T, Albillos A, Moreau R, Salerno F, Abraldes J. Introduction and Survey Results. 2016, 303-309. DOI: 10.1007/978-3-319-23018-4_30.Peer-Reviewed Original ResearchComplications of cirrhosisRecurrent variceal hemorrhageVariceal hemorrhageDifferent prognostic stagesEndpoints of trialsPresence of varicesInvestigation of patientsCompensated patientsCurrent therapiesSpecific therapyDifferent prognosisPrognostic stageHemorrhageCirrhosisPatientsComplicationsTherapyDifferent efficacyVaricesDecompensationPrognosisRecurrence
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply